Probiotic Lactobacillus acidophilus enhances the immunogenicity of an oral rotavirus vaccine in gnotobiotic pigs

Zhang, Wei; Azevedo, Marli S.P.; Wen, Ke; González, Ana María; Saif, Linda J.; Li, Guohua; Yousef, Ahmed E.; Yuan, Lijuan

doi:10.1016/j.vaccine.2008.04.070

Cited by 111 publications

(109 citation statements)

References 30 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…Although these two strains were not able to reduce virus replication into IPEC-J2 cells, they could differently modulate cellular immune response. Indeed, LA treatment prior to RV infection significantly increased virus-induced IL-6 response, consistent with the adjuvant effect of this strain, in potentiating immunogenicity of an oral RV vaccine in a gnotobiotic pig model (Zhang et al 2008). On the contrary, LGG treatment post-RV infection downregulated the IL-6 response, confirming the well documented anti-inflammatory effect of LGG.…”

Section: Probiotics Used In Pig Intestinal Cells Challenged With Virusessupporting

confidence: 77%

Immunomodulating effects of probiotics for microbiota modulation, gut health and disease resistance in pigs

Roselli

Pieper

Rogel–Gaillard

et al. 2017

Animal Feed Science and Technology

View full text Add to dashboard Cite

General rightsThis document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms HIGHLIGHTS-Updated literature overview about probiotics, prebiotics and synbiotics on pig gut health is provided -Both in vivo studies performed in pigs and in vitro studies conducted in pig intestinal cell lines are described -A critical outcome of the described results is provided -The concept of "proxy measurements" for pig gut health is widely discussed -The link between gut microbiota and mucsal immune system is described Abstract:Probiotics are live microorganisms that can confer a health benefit on the host, and amongst various mechanisms probiotics are believed to exert their effects by production of antimicrobial substances, competition with pathogens for adhesion sites and nutrients, enhancement of mucosal barrier integrity and immune modulation. Through these activities probiotics can support three core benefits for the host: supporting a healthy gut microbiota, a healthy digestive tract and a healthy immune system. More recently, the concept of combining probiotics and prebiotics, i.e. synbiotics, for the beneficial effect on gut health of pigs has attracted major interest, and examples of probiotic and prebiotic benefits for pigs are pathogen inhibition and immunomodulation. Yet, it remains to be defined in pigs, what exactly is a healthy gut. Because of the high level of variability in growth and feed conversion between individual pigs in commercial production systems, measuring the impact of probiotics on gut health defined by improvements in overall productivity requires large experiments. For this reason, many studies have concentrated on measuring the effects of the feed additives on proxies of gut health including many immunological measures, in more controlled experiments. With the major focus of studying the balance between gut microbiology, immunology and physiology, and the potential for prevention of intestinal disorders in pigs, we therefore performed a literature review of the immunomodulatory effects of probiotics, either alone or in combination with prebiotics, based on in vivo, in vitro and ex vivo porcine experiments. A 3 consistent number of studies showed the potential capacity in terms of immunomodulatory activities of these feed additives in pigs, but contrasting results can also be obtained from the literature.Reasons for this are not clear but could be related to differences with respect to the probiotic strain used, experimental settings, diets, initial microbiota colonization, administration route, time and frequency of administration of the probiotic strain and sampling for analysis. Hence, the use of proxy measurements of enteric health based on observable immunological parameters presents significant problems at the moment, and cannot be considered robust, reliable predictors of the probiotic activity in vivo, in relation to pig gut health. In c...

show abstract

Section: Probiotics Used In Pig Intestinal Cells Challenged With Virusessupporting

confidence: 77%

Immunomodulating effects of probiotics for microbiota modulation, gut health and disease resistance in pigs

Roselli

Pieper

Rogel–Gaillard

et al. 2017

Animal Feed Science and Technology

View full text Add to dashboard Cite

show abstract

“…The homologous/heterologous virus-neutralizing (VN) antibody titers against PRV G9P [13], HRV Wa G1P [8], PRV OSU G5P [7], and PRV Gottfried G4P [6] in convalescent-phase/hyperimmune sera were determined by a fluorescent-focus neutralization (FFN) test, as previously described (43). The VN titer was expressed as the reciprocal of the highest dilution of serum that reduced the number of infected-cell foci by 80%.…”

Section: Methodsmentioning

confidence: 99%

Comparative In Vitro and In Vivo Studies of Porcine Rotavirus G9P[13] and Human Rotavirus Wa G1P[8]

Shao

Fischer

Kandasamy

et al. 2016

J Virol

Self Cite

View full text Add to dashboard Cite

The changing epidemiology of group A rotavirus (RV) strains in humans and swine, including emerging G9 strains, poses new challenges to current vaccines. In this study, we comparatively assessed the pathogenesis of porcine RV (PRV) G9P IMPORTANCEThe changing epidemiology of porcine and human group A rotaviruses (RVs), including emerging G9 strains, may compromise the efficacy of current vaccines. An understanding of the pathogenesis and genetic, immunological, and biological features of the new emerging RV strains will contribute to the development of new surveillance and prevention tools. Additionally, studies of cross-protection between the newly identified emerging G9 porcine RV strains and a human G1 RV vaccine strain in a susceptible host (swine) will allow evaluation of G9 strains as potential novel vaccine candidates to be included in porcine or human vaccines. R otavirus (RV), a member of the Reoviridae family, has a double-stranded RNA genome with 11 segments (1). It is the most common pathogen in cases of acute gastroenteritis in children under 5 years of age (1, 2). In the United States, it causes approximately $1 billion in annual costs due to RV-associated physician visits, emergency department visits, and hospitalizations (3-5). Annually, RV causes 440,000 deaths in children under 5 years of age worldwide, with most occurring in developing countries (4). RVs also infect young domestic animals, including calves and piglets (1). RV is responsible for annual mortality rates of 7 to 20% and 3 to 15% in nursing and weaned piglets, respectively (6). The high prevalence of RV in swine results in large economic losses to the pork industry (6). Treatment of RV infection is possible only by replacing fluids and electrolyte losses, because no specific antiviral therapy is available. Therefore, effective RV vaccines are crucial to prevent morbidity and mortality in both young children and animals (7,8).RVs are classified into 8 groups, groups A to H, as determined by viral structural protein 6 (VP6) (9-11). Based on the outer capsid VP4 (P genotype)-and VP7 (G genotype)-encoding genes, a binary classification system has been established for RVs (12). Overall, there are at least 26 G genotypes and 33 P genotypes of group A RVs (RVAs) (13,14). Globally, the G1 to G4, P[4], P[6], and P [8] genotypes are the most prevalent human RVAs (15). RVA G1P[8] is a common human strain worldwide and constitutes Ͼ70% of prevalent strains in North America, Australia, and Europe but only 20 to 35% of circulating strains in South America, Asia, and Africa (5,(15)(16)(17). G5 and P[7] are historically considered the most prevalent G and P RVA genotypes in swine, respectively (18). However, recent studies have shown that RVA G9 and G12 genotypes are emerging worldwide in humans and swine (2,(19)(20)(21)(22)(23).

show abstract

“…35,63 Only one small RRV-TV study in Finnish infants randomized to lactobacillus GG has been able to demonstrate an improvement in IgA seroconversion. 35 No other study has demonstrated improved correlates of rotavirus immunity associated with adjuvant use.…”

Section: Rotavirus Vaccine Adjuvantsmentioning

confidence: 99%

Options for improving effectiveness of rotavirus vaccines in developing countries

Tissera

Cowley

Bogdanovic-Sakran

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Rotavirus gastroenteritis is a leading global cause of mortality and morbidity in young children due to diarrhea and dehydration. Over 85% of deaths occur in developing countries. In industrialised countries, 2 live oral rotavirus vaccines licensed in 2006 quickly demonstrated high effectiveness, dramatically reducing severe rotavirus gastroenteritis admissions in many settings by more than 90%. In contrast, the same vaccines reduced severe rotavirus gastroenteritis by only 30-60% in developing countries, but have been proven life-saving. Bridging this "efficacy gap" offers the possibility to save many more lives of children under the age of 5. The reduced efficacy of rotavirus vaccines in developing settings may be related to differences in transmission dynamics, as well as host luminal, mucosal and immune factors. This review will examine strategies currently under study to target the issue of reduced efficacy and effectiveness of oral rotavirus vaccines in developing settings.

show abstract

Probiotic Lactobacillus acidophilus enhances the immunogenicity of an oral rotavirus vaccine in gnotobiotic pigs

Cited by 111 publications

References 30 publications

Immunomodulating effects of probiotics for microbiota modulation, gut health and disease resistance in pigs

Immunomodulating effects of probiotics for microbiota modulation, gut health and disease resistance in pigs

Comparative In Vitro and In Vivo Studies of Porcine Rotavirus G9P[13] and Human Rotavirus Wa G1P[8]

Options for improving effectiveness of rotavirus vaccines in developing countries

Contact Info

Product

Resources

About